What's New at CBER You are subscribed to  What's New at CBER for the U.S. Food & Drug Administration (FDA) The following links have been updated recently: Posted: 9/29/2021 CBER Advanced Technologies Program Extramural Research Funding CBER Advanced Technologies Program Expiration Date Extension for Dextran 40 (10% LMD in 5% Dextrose Injection) Lot 09141JT through May 1, 2022 and 12090JT through August 1, 2022 Expiration Date Extension for Dextran 40 (10% LMD in 0.9% Sodium Chloride Injection) Lot 07011JT through June 1, 2022 Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Guidance for Industry Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Draft Guidance for Industry

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA